A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better.

Mice treated with higher αCSF1R dose had more CD163 + cells compared to the group that received lower αCSF1R dose, but the differences did not reach statistical significance (Fig. 5 a).

also in 111,027 other papers